Xeris Biopharma Holdings, Inc. 8-K

What Happened
Xeris Biopharma Holdings, Inc. announced on February 26, 2026, that its subsidiaries, Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited, filed a patent infringement lawsuit under the Hatch‑Waxman Act in the U.S. District Court for the District of New Jersey. The suit challenges two unnamed pharmaceutical companies (each an "ANDA Filer") that submitted Abbreviated New Drug Applications (ANDAs) to the FDA seeking approval to commercially manufacture, use, or sell a generic version of RECORLEV® (levoketoconazole). The company attached a press release announcing the action as Exhibit 99.1 to its Form 8‑K.

Key Details

• Press release announcing the lawsuit dated February 26, 2026; Form 8‑K filed February 27, 2026.
• Plaintiffs: Xeris Pharmaceuticals, Inc. and Strongbridge Dublin Limited.
• Defendants: two unnamed ANDA filers that submitted ANDAs for a generic version of RECORLEV (levoketoconazole).
• Legal basis: patent infringement suit under the Hatch‑Waxman Act in the U.S. District Court for the District of New Jersey.

Why It Matters
This legal action is aimed at blocking or delaying FDA approval and commercial launch of generic versions of RECORLEV, Xeris’s marketed product for which levoketoconazole is the active ingredient. For investors, the outcome could affect RECORLEV’s market exclusivity and future revenue—successful enforcement could preserve sales, while an adverse result could enable generic competition. The filing itself does not disclose financial impacts or timelines.